A Durham-based stent-maker has raised about $25.8 million of a $30 million equity and debt offering.
According to a document Micell Technologies Inc. filed with the SEC on Friday, the date of first sale was June 20.
Micell’s lead product is MiStent SES. It is available for sale outside the U.S., but has not yet received FDA approval, according to the company.
Back in 2013, Micell inked a development and distribution agreement for the stent system in China with Hefei Life Science Technology Park…
A Durham-based stent-maker has raised about $25.8 million of a $30 million equity and debt offering.
According to a document Micell Technologies Inc. filed with the SEC on Friday, the date of first sale was June 20.
Micell’s lead product is MiStent SES. It is available for sale outside the U.S., but has not yet received FDA approval, according to the company.
Back in 2013, Micell inked a development and distribution agreement for the stent system in China with Hefei Life Science Technology Park…